CURX Stock Price, Chart, Stats & News

Curanex Pharmaceuticals Inc Common Stock
Save
7.87M
Market cap
–
Current P/E
–
Forward P/E
CURX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -8.90% |
ROE | -33.34% |
D/E | 0.00x |
Interest coverage ratio | -150.52x |
CURX valuation
P/E | – |
P/S | – |
P/B | 0.86x |
P/CF | -1.28x |
P/FCF | -1.41x |
P/OCF | -1.28x |
PEG | 0.02x |
EV multiple | -16.67x |
About
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Similar securities
Based on sector and market capitalization
Report issue










